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better will earn three CME credits.1. According to the 2005 AUA guidelines, acute complication rate
and mortality rate for PCNL were about:
A. 7%, 3%
B. 6%, 3%
C. 6%, 2%
D. 5%, 2%
E. 5%, 1%
Urol Sci 2012;23(3):67-9
2. Which of the following treatment conditions would make
retrograde endoscopic lithotripsy (REL) an alternative treat-
ment option?
A. In morbidly obese patients
B. In patients on anticoagulant therapy
C. All of the above
D. None of the above
Urol Sci 2012;23(3):67-91879-5226/$ e see front matter
doi:10.1016/S1879-5226(12)00072-33. Which is correct?
A. Although a large number of therapeutic agents are available
for treating bladder diseases, most of them are adminis-
tered through the per-oral route
B. Systemic administration of these therapeutic agents
requires administration of large doses, but only a small
fraction actually reaches the bladder
C. Delivery of a therapeutic agent directly into the bladder
greatly improves the exposure of the affected bladder lining
to the agent, and this is of even greater signiﬁcance in the
case of drug-resistant targets which require a much-higher
dose of the drug
D. Hyaluronic acid, heparin, and chondroitin sulfate restore
the barrier function lost due to epithelial dysfunction in
interstitial cystitis
E. All of the above
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A. The urothelial barrier restricts the movement of drugs after
intravesical administration and also restricts the action of
the active drug fraction in the urine
B. The urothelium, responsible for amultitude of physiological
activities, is not only effective in blocking the entry of urine
contents but is also equally effective in blocking the entry of
instilled drugs
C. Urothelial tight junctions are comprised of a dense network
of cytoplasmic proteins (zonula occludens-1), cytoskeletal
elements, and transmembrane proteins (occludin and
claudins) and have the highest recorded paracellular
resistance of all epithelia measured to date
D. The apical plasma membrane of the urothelium contains
speciﬁc proteins, uroplakins, which account for the trans-
cellular resistance
E. All of the above
Urol Sci 2012;23(3):70-7
5. Which one of the following is not a frequently occurring
clinical symptom and sign in testicular torsion?
A. Sudden-onset scrotal pain
B. Scrotal swelling
C. Fever
D. Loss of the cremasteric reﬂex
Urol Sci 2012;23(3):85-6
6. Which one of the following signs can be found in testicular
torsion?
A. Staghorn sign
B. Prehn’s sign
C. Cortical rim sign
D. Balloon on a string sign
Urol Sci 2012;23(3):85-67. Which one of the following imaging modalities is the most
reliable in the diagnosis of testicular torsion?
A. Intravenous urography (IVU)
B. Computed tomography (CT)
C. Voiding cystourethrography (VCUG)
D. Color Doppler ultrasound (CDU)
Urol Sci 2012;23(3):85-6
8. Which one of the following statements about prostatic ductal
adenocarcinoma is correct?
A. It is an exclusively centrally located neoplasm
B. It only arises from large prostatic ducts of transitional zone
C. It is of Müllerian origin, therefore it can be called endo-
metrioid carcinoma of the prostate
D. It always presents as a pure form and is not admixed with
usual acinar adenocarcinoma
E. It is an aggressive cancer equivalent to Gleason pattern 4
adenocarcinoma
Urol Sci 2012;23(3):87-8
9. The treatment of choice for prostatic ductal adenocarcinoma is
analogous to that of:
A. Urothelial carcinoma
B. Low-grade prostatic adenocarcinoma of transitional zone
C. Usual acinar prostatic adenocarcinoma
D. Benign prostatic hyperplasia
E. High grade prostatic intraepithelial neoplasia
Urol Sci 2012;23(3):87-8
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Answers:
1. (C) 2. (E) 3. (B) 4. (E) 5. (E) 6. (E) 7. (A) 8. (D) 9. (D)
